Abbott Laboratories [NYSE: ABT] jumped around 0.14 points on Wednesday, while shares priced at $120.11 at the close of the session, up 0.12%. The company report on April 6, 2021 that Abbott’s XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients.
– New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
– XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that demonstrated safe treatment of stented patients with one-month or three-month use of DAPT.
Abbott Laboratories stock is now 9.70% up from its year-to-date (YTD) trading value. ABT Stock saw the intraday high of $120.88 and lowest of $119.60 per share. The company’s 52-week high price is 128.54, which means current price is +11.99% above from all time high which was touched on 02/12/21.
Compared to the average trading volume of 5.26M shares, ABT reached a trading volume of 4299355 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Abbott Laboratories [ABT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $135.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 28, 2021. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on September 11, 2020, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $84, while Goldman analysts kept a Sell rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 2.40, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 6.19. The Price to Book ratio for the last quarter was 6.51, with the Price to Cash per share for the same quarter was set at 4.00. Price to Free Cash Flow for ABT in the course of the last twelve months was 67.76 with Quick ratio for the last quarter at 1.30.
How has ABT stock performed recently?
Abbott Laboratories [ABT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.30. With this latest performance, ABT shares gained by 3.87% in over the last four-week period, additionally plugging by 10.64% over the last 6 months – not to mention a rise of 45.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 51.66, with the RSI for the last a single of trading hit 52.21, and the three-weeks RSI is set at 51.93 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 120.69, while it was recorded at 119.74 for the last single week of trading, and 108.92 for the last 200 days.
Abbott Laboratories [ABT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +15.29 and a Gross Margin at +50.21. Abbott Laboratories’s Net Margin is presently recorded at +12.86.
Return on Total Capital for ABT is now 10.24, given the latest momentum, and Return on Invested Capital for the company is 8.83. Return on Equity for this stock inclined to 13.93, with Return on Assets sitting at 6.34. When it comes to the capital structure of this company, Abbott Laboratories [ABT] has a Total Debt to Total Equity ratio set at 60.67. Additionally, ABT Total Debt to Total Capital is recorded at 37.76, with Total Debt to Total Assets ending up at 27.42. Long-Term Debt to Equity for the company is recorded at 59.26, with the Long-Term Debt to Total Capital now at 36.89.
Reflecting on the efficiency of the workforce at the company, Abbott Laboratories [ABT] managed to generate an average of $40,817 per employee. Receivables Turnover for the company is 5.85 with a Total Asset Turnover recorded at a value of 0.49.Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.70.
Earnings analysis for Abbott Laboratories [ABT]
With the latest financial reports released by the company, Abbott Laboratories posted 0.65/share EPS, while the average EPS was predicted by analysts to be reported at 0.58/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 15.58%.
Insider trade positions for Abbott Laboratories [ABT]
There are presently around $157,032 million, or 75.80% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 147,272,920, which is approximately -0.596% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 133,426,810 shares of the stock with an approximate value of $16.03 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $10.38 billion in ABT stock with ownership of nearly -1.166% of the company’s market capitalization.
Positions in Abbott Laboratories stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,194 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 42,066,152 shares. Additionally, 983 investors decreased positions by around 42,309,861 shares, while 342 investors held positions by with 1,223,023,018 shares. The mentioned changes placed institutional holdings at 1,307,399,031 shares, according to the latest SEC report filing. ABT stock had 243 new institutional investments in for a total of 4,112,958 shares, while 61 institutional investors sold positions of 3,478,698 shares during the same period.